Medindia20d
Health Canada Authorizes Vabysmo® (faricimab injection) Pre-Filled Syringe (PFS) for Three Leading Causes of Vision Loss
Vabysmo Product Monograph, December 13, 2024. 2. Song P, et al. Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, ...
Pharmabiz18d
Health Canada authorizes Roche’s Vabysmo pre-filled syringe for three leading causes of vision loss
Mississauga, Ontario Tuesday, January 21, 2025, 14:00 Hrs [IST] ...
Business Wire3d
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...
With FDA approval, Genentech turns eye implant's focus to diabetes
Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...
Pharmabiz2d
Roche’s Susvimo receives US FDA approval for the treatment of diabetic macular edema
Roche’s Susvimo receives US FDA approval for the treatment of diabetic macular edema: Basel Thursday, February 6, 2025, 11:00 Hrs [IST] Roche announced that the US Food and Drug ...
PharmiWeb3d
FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...
Hosted on MSN29d
15 Ways That Heart Disease Affects Your Eyes
Retinal vein occlusion is a reminder of how interconnected ... damages the blood vessels in the retina. This condition can cause bleeding, fluid leakage, and swelling in the retina, leading ...
F. Hoffmann-La Roche Ltd: Roche reports strong 2024 results with 7% sales growth; fourth quarter marks third straight quarter of 9% growth
Group sales grew by 7%1 at constant exchange rates (CER; 3% in CHF), driven by strong demand for both medicines and diagnostics.Excluding COVID-19, Group sales increased by 9%.
bjo.bmj28d
Branch retinal vein occlusion and optic nerve head topographic parameters: the Singapore Indian eye study
Australia Aim To examine the association between branch retinal vein occlusion (BRVO) and quantitative optic disc topographic parameters. Methods The Singapore Indian Eye Study (SINDI) is a population ...